Gender-specific lipid profiles in patients with bipolar disorder

Journal of Psychiatric Research

Volumn 45, Issue 8, 2011, Pages 1036-1041

  Vemuri, Mytilee ^a   Kenna, Heather A ^a   Wang, Po W ^a   Ketter, Terence A ^a   Rasgon, Natalie L ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Bipolar disorder; Dyslipidemia; Gender; Insulin resistance; Metabolic

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CLOZAPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMOTRIGINE; LITHIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; VALPROIC ACID;

ADULT; AGED; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BODY MASS; BODY WEIGHT; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EXPOSURE; DYSLIPIDEMIA; EDUCATIONAL STATUS; ETHNICITY; FEMALE; HUMAN; INSULIN RESISTANCE; LABORATORY TEST; LIPID ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL PATIENT; OUTPATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79960589405     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2011.02.002     Document Type: Article

References (40)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., nfante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999, 156:1686-1696.
2. Cholesterol statistics 2010, American Heart Association, American Heart Association.
3. Birkenaes A., Birkeland K., Engh J., Farden A. Dyslipidemia independent of body mass in antipsychotic-treated patients under Real-life conditions. Journal of Clinical Psychopharmacology 2008, 28:132-137.
4. Bowden C.L., Calabrese J.R., McElroy S.L., Gyulai L., Wassef A., Petty F., et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Archives of General Psychiatry 2000, 57:481-489.
5. Bowden CL, Vieta E, et al. A 6-month, randomized, placebo-controlled, double-blind trial of ziprasidone plus a mood stabilizer in subjects with bipolar I disorder. In: 2009, Eighth International Conference on Bipolar Disorder, Pittsburgh, June 25-27. 2009.
6. Dennehy E.B., Bauer M.S., Perlis R.H., Kogan J.N., Sachs G.S. Concordance with treatment guidelines for bipolar disorder: data from the systematic treatment enhancement program for bipolar disorder. Psychopharmacology Bulletin 2007, 40:72-84.
7. Fagiolini A., Frank E., Scott J.A., Turkin S., Kupfer D.J. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disorder 2005, 7:424-430.
8. Fiedorowicz J.G., Palagummi N.M., Forman-Hoffman V.L., Miller del D., Haynes W.G. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Annals of Clinical Psychiatry 2008, 20:131-137.
9. Garcia-Portilla M.P., Saiz P.A., Benabarre A., Sierra P., Perez J., Rodriguez A., et al. The prevalence of metabolic syndrome in patients with bipolar disorder. Journal of Affective Disorders 2008, 106:197-201.
10. Gardner C.D., Winkleby M.A., Fortmann S.P. Population frequency distribution of non-high-density lipoprotein cholesterol (Third National Health and Nutrition Examination Survey [NHANES III], 1988-1994). American Journal of Cardiology 2000, 86:299-304.
11. Gostynski M., Gutzwiller F., Kuulasmaa K., Doring A., Ferrario M., Grafnetter D., et al. Analysis of the relationship between total cholesterol, age, body mass index among males and females in the WHO MONICA Project. Int J Obes Relat Metab Disord 2004, 28:1082-1090.
12. Keck P.E., Calabrese J.R., McQuade R.D., Carson W.H., Carlson B.X., Rollin L.M., et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. Journal of Clinical Psychiatry 2006, 67:626-637.
13. Kilbourne A.M., Cornelius J.R., Han X., Pincus H.A., Shad M., Salloum I., et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disorder 2004, 6:368-373.
14. Kinder L.S., Carnethon M.R., Palaniappan L.P., King A.C., Fortmann S.P. Depression and the metabolic syndrome in young adults: findings from the third National Health and Nutrition Examination Survey. Psychosomatic Medicine 2004, 66:316-322.
15. Ley C.J., Lees B., Stevenson J.C. Sex- and menopause-associated changes in body-fat distribution. American Journal of Clinical Nutrition 1992, 55:950-954.
16. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 2005, 80:19-32.
17. McLaughlin T., Reaven G., Abbasi F., Lamendola C., Saad M., Waters D., et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?. American Journal of Cardiology 2005, 96:399-404.
18. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluationand treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. NCEP.
19. Newcomer J.W. Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses. Journal of Clinical Psychiatry 2009, 70(Suppl. 3):30-36.
20. Quiroz J.A., Yatham L.N., Palumbo J.M., Karcher K., Kushner S., Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biological Psychiatry 2010, 68:156-162.
21. Rasgon N., Jarvik L. Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis. The Journals of Gerontology, Series A: Medical Sciences 2004, 59:178-183. discussion 184-192.
22. Rasgon N.L., Carter M.S., Elman S., Bauer M., Love M., Korenman S.G. Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review. Curr Drug Targets Immune Endocr Metabol Disord 2002, 2:97-102.
23. Razay G., Heaton K.W., Bolton C.H. Coronary heart disease risk factors in relation to the menopause. QJM 1992, 85:889-896.
24. Regitz-Zagrosek V., Lehmkuhl E., Mahmoodzadeh S. Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. Gender Medicine 2007, 4(Suppl. B):S162-S177.
25. Sachs G., Bowden C., Calabrese J.R., Ketter T., Thompson T., White R., Bentley B. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disorder 2006, 8:175-181.
26. Sachs G.S., Guille C., McMurrich S.L. A clinical monitoring form for mood disorders. Bipolar Disorder 2002, 4:323-327.
27. Sachs G.S., Thase M.E., Otto M.W., Bauer M., Miklowitz D., Wisniewski S.R., et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biological Psychiatry 2003, 53:1028-1042.
28. Seidell J.C., Cigolini M., Charzewska J., Ellsinger B.M., Bjorntorp P., Hautvast J.G. Fat distribution and gender differences in serum lipids in men and women from four European communities. Atherosclerosis 1991, 87:203-210.
29. Sicras A., Rejas J., Navarro R., Serrat J., Blanca M. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. Bipolar Disord 2008, 10:607-616.
30. Sicras-Mainar A., Blanca-Tamayo M., Rejas-Gutierrez J., Navarro-Artieda R. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database. European Psychiatry 2008, 23:100-108.
31. Stemmle P.G., Kenna H.A., Wang P.W., Hill S.J., Ketter T.A., Rasgon N.L. Insulin resistance and hyperlipidemia in women with bipolar disorder. Journal of Psychiatric Research 2009, 43:341-343.
32. Teixeira P.J., Rocha F.L. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Revista Brasileira de Psiquiatria 2007, 29:330-336.
33. Tohen M., Calabrese J.R., Sachs G.S., Banov M.D., Detke H.C., Risser R., et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. American Journal of Psychiatry 2006, 163:247-256.
34. Van Winkel R., De Hert M., Hanssens L., Wampers M., Scheen A., Peuskens J. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disorder 2008, 10:342-348.
35. Vieta E., Cruz N., Garcia-Campayo J., de Arce R., Manuel Crespo J., Valles V., et al. A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. International Journal of Neuropsychopharmacology 2008, 11:445-452.
36. Wang P.W., Sachs G.S., Zarate C.A., Marangell L.B., Calabrese J.R., Goldberg J.F., et al. Overweight and obesity in bipolar disorders. Journal of Psychiatric Research 2006, 40:762-764.
37. Weiden P.J. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. Journal of Clinical Psychiatry 2007, 68(Suppl. 4):34-39.
38. Weisler R.H., Hirschfeld R., Cutler A.J., Gazda T., Ketter T.A., Keck P.E., et al. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs 2006, 20:219-231.
39. Weisler RH, Nolen WA. Quetiapine or lithium versus placebo for maintenance treatment of bipolar I disorder after stabilization on Quetiapine. In: International Conference on Bipolar Disorder, Pittsburgh, June 25-27, 2009.
40. Williams C.M. Lipid metabolism in women. Proceedings of the Nutrition Society 2004, 63:153-160.